Activity

The closed technique had more discoloration (P<0.001) and a delayed response to the cold test (P=0.021). In general, patients were satisfied with both techniques but considered the treatment time to be very long.

A closed surgical exposure of palatally impacted maxillary canines is preferred in terms of aesthetics when measured with the MCAI. There was no difference between the 2 techniques in terms of periodontal outcome. Canines treated with a closed exposure tended to have a darker color and delayed response to cold testing.

A closed surgical exposure of palatally impacted maxillary canines is preferred in terms of aesthetics when measured with the MCAI. There was no difference between the 2 techniques in terms of periodontal outcome. Canines treated with a closed exposure tended to have a darker color and delayed response to cold testing.

The evaluation of online information regarding orthodontic temporary anchorage devices (TADs) is lacking despite the increase in their use by orthodontists. This cross-sectional study aimed to investigate the quality of information regarding TADs available on the Internet to the general public.

Two search terms (“orthodontic temporary anchorage device” and “orthodontic miniscrew”) were entered separately into a total of 5 search engines. The DISCERN instrument, Journal of the American Medical Association (JAMA) benchmarks, and Health on the Net Foundation Code of Conduct were used to evaluate the quality of information contained within Web sites that satisfied the inclusion and/or exclusion criteria. Web site readability was assessed via the Simple Measure of Gobbledygook and Flesch Reading Ease Score tools. Descriptive statistical analyses and Cohen’s kappa intrarater reliability tests were performed.

Thirty-one Web sites were evaluated. Most were authored by orthodontists (77.4%) and originated from tality and easily readable content.

The quality of information related to TADs on the Internet is moderate. UGT8-IN-1 inhibitor The usefulness of the information may be further reduced because it was beyond the readability of the average member of the general public. Web site authors should consider the use of additional expertise, quality of information tools, and readability formulas to ensure high-quality and easily readable content.Growth modification is a feasible approach for the treatment of skeletal Class II malocclusion. A positive association was found between the lateral functional shift of the mandible due to occlusal prematurities and skeletal changes. This finding is reminiscent of an equivalent anteroposterior skeletal effect of the anterior functional shift of the mandible. Inclined planes can be considered as a form of premature contact. In this case, bonded occlusal maxillary and mandibular bite raisers were used to create occlusal prematurities artificially. These bonded inclined bite raisers are used in conjunction with full-time light short Class II elastics. The results showed an improvement in profile convexity and achievement of Class I canines and molars. The bonded inclined bite raisers combined with light and short intermaxillary elastics can correct Class II malocclusion and improve the soft tissue profile.

This study aimed to evaluate the effects of 3 different fixed or removable functional appliances on the soft tissue changes in patients with Class II Division 1 malocclusion using 3-dimensional images.

A total of 60 patients with Class II Division 1 malocclusion (38 girls and 22 boys; mean age, 12.35±1.01years) were treated with 3 different functional appliances, namely, Twin-block (TB) (group TB, n=20), mono-block (MB) (group MB, n=20), or Herbst (H) (group H, n=20) for 9.55±1.46months. Three-dimensional photographs of each patient were taken at the baseline and the end of the therapy with a 3dMD Face system (3dMD, Atlanta, Ga). Statistical analyses were performed using the dependent samples t test, 1-way analysis of variance, Kruskal-Wallis, Mann-Whitney U, and Wilcoxon signed rank tests.

No statistically significant differences were detected for soft tissue changes except for the lower facial width found, at least in group H (P<0.05). Volumetric differences in the mandible were similar between the groups (P>0.05). A statistically significant decrease in total facial height and an increase in convexity angle and facial depth were detected in all groups after treatment compared with the baseline (P<0.05). The upper and lower facial height, lower lip height, and nasal width were statistically significantly increased in the TB and MB groups after treatment compared with the baseline (P<0.05) and similar to those in group H (P>0.05).

TB, MB, and H appliances may promote the facial soft tissue profile, including volumetric improvement, in the mandibular region.

TB, MB, and H appliances may promote the facial soft tissue profile, including volumetric improvement, in the mandibular region.Chicken blood has limited utilization despite its high protein content. Production of a blood hydrolysate exhibiting angiotensin I-converting enzyme (ACE)-inhibitory activity would be means of valorizing chicken blood. The optimized conditions used to produce chicken blood corpuscle hydrolysate (BCH) by Alcalase were 51.1°C, 4% enzyme, and pH 9.6 for 6 h, resulting in a 35.8% degree of hydrolysis and 37.7% ACE inhibition at a peptide concentration of 0.2 mg/mL. The permeate of a 1-kDa membrane, BCH-III, showed a 2.5-fold increase in ACE inhibition compared with that of BCH. BCH-III was resistant to in vitro gastrointestinal digestion, whereas the BCH digesta exhibited an increased ACE-inhibitory activity after digestion. Both BCH and BCH-III were rich in hydrophobic amino acids. A single administration of BCH and BCH-III to spontaneously hypertensive rats at concentrations of 600 and 100 mg/kg, respectively, lowered the systolic blood pressure by -57.7 and -70.9 mmHg, respectively, 6 h after oral administration compared with the control group. The blood pressure-lowering effect of the 600 mg/kg BCH dose was comparable with that of the 100 mg/kg BCH-III dose after 4 wk of oral administration. Both BCH and BCH-III could be developed for use as nutraceutical products with antihypertensive effects.